Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca-Reference-Cited by-同舟云学术

Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca

Published:2022-02 Issue: Volume:614 Page:121387
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Anane-Adjei Akosua B.,Jacobs Esther^ORCID,Nash Samuel C.,Askin Sean^ORCID,Soundararajan Ramesh^ORCID,Kyobula Mary,Booth Jonathan,Campbell Andrew^ORCID

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference132 articles.

1. Hot Melt Extrusion: Development of an Amorphous Solid Dispersion for an Insoluble Drug from Mini-scale to Clinical Scale;Agrawal;AAPS PharmSciTech,2016

2. Characterization and stability of ternary solid dispersions with PVP and PHPMA;Al-Obaidi;International Journal of Pharmaceutics,2011

3. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System;Baghel;Molecular Pharmaceutics,2018

4. A classification system to assess the crystallization tendency of organic molecules from undercooled melts;Baird;J Pharm Sci,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of hot melt extrusion technology: Advantages, applications, key factors and future prospects;Journal of Drug Delivery Science and Technology;2024-09

2. Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability;AAPS PharmSciTech;2024-08-13

3. Supercritical Fluids: An Innovative Strategy for Drug Development;Bioengineering;2024-08-04

4. Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023;International Journal of Pharmaceutics: X;2024-06

5. Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform;Clinical Pharmacology in Drug Development;2024-05-29